Harrow Health, Inc. (HROW) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Harrow Health, Inc. on July 29, 2019. The report details a material definitive agreement entered into by Stowe Pharmaceuticals, Inc., a subsidiary of Harrow Health, Inc.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The financial impact is limited to the terms of a new license agreement:
- Equity Issuance: 1,750,000 shares of common stock issued to TGV-Health, LLC and TGV-Ophthalnix, LLC.
- Royalty Obligations: Future royalty payments equal to a low single-digit percentage of net sales from products based on the licensed intellectual property.
- Milestone Payments: Future contingent payments required upon the development of the drug candidate STE-006 and related products.
Material Changes
The primary material change is the acquisition of intellectual property rights for use in the ophthalmic and otic fields related to the proprietary drug candidate STE-006. This expands the Company's pipeline through a partnership with TGV-Health, LLC and TGV-Ophthalnix, LLC (collectively "TGV").
Outlook, Risks, and Management Commentary
Under the agreement, Stowe is obligated to use commercially reasonable efforts to research, develop, and commercialize products based on the acquired intellectual property. TGV is obligated to cooperate in transferring intellectual property and assist in obtaining and protecting patent rights. The filing notes that the description provided is brief and does not purport to be a complete description of the rights and obligations.
Key Facts for Investor Verification
- Verify the dilution impact of the 1,750,000 shares issued to TGV.
- Confirm the specific definition of "net sales" and the exact royalty percentage (described only as "low single digit") in the full agreement.
- Review the specific development milestones and associated payment amounts for STE-006.
- Assess the current development stage of STE-006 and the timeline for commercialization.